In Human Genome Sciences v Eli Lilly, the UK's Supreme Court debated whether the UK has correctly followed European patent law on industrial application. The case involves a split between the England & Wales Court of Appeal and the EPO Technical Board of Appeal (TBA). The UK courts have revoked HGS's patent for the Neutrokine-a protein – even though the appellant's amended set of claims had been accepted by the TBA. This is the first patent case to be heard by the UK Supreme Court. It has been asked to rule whether the Court of Appeal correctly applied the principles of law established by the EPO relating to Article 57 of the EPC and whether the amended claims are sufficient to maintain the patent under UK law. On day two of the three-day hearing, HGS's patent was said to contain a "lot of guff" according to Lord Justice Neuberger, but whether that should invalidate the patent was the key question. The decision is expected before the end of this year.